Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tarsus Pharmaceuticals (TARS) Equity Income (2021 - 2024)

Tarsus Pharmaceuticals (TARS) has 4 years of Equity Income data on record, last reported at -$6000.0 in Q2 2024.

  • For Q2 2024, Equity Income fell 140.0% year-over-year to -$6000.0; the TTM value through Dec 2024 reached -$591000.0, down 328.19%, while the annual FY2024 figure was -$591000.0, 328.19% down from the prior year.
  • Equity Income reached -$6000.0 in Q2 2024 per TARS's latest filing, up from -$585000.0 in the prior quarter.
  • Across five years, Equity Income topped out at $420000.0 in Q4 2023 and bottomed at -$591000.0 in Q4 2021.
  • Average Equity Income over 4 years is -$108272.7, with a median of -$65000.0 recorded in 2023.
  • Peak YoY movement for Equity Income: surged 624.14% in 2023, then tumbled 800.0% in 2024.
  • A 4-year view of Equity Income shows it stood at -$591000.0 in 2021, then soared by 109.81% to $58000.0 in 2022, then soared by 624.14% to $420000.0 in 2023, then plummeted by 101.43% to -$6000.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Equity Income were -$6000.0 in Q2 2024, -$585000.0 in Q1 2024, and $420000.0 in Q4 2023.